BO-112 clinical trials
Also written BO-112.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses BO-112 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Highlight Therapeutics (4) · Jonsson Comprehensive Cancer Center (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test BO-112.
- Dec 2026Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)Phase 2 · Highlight Therapeutics
- Jan 2027Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaPhase 1 · Jonsson Comprehensive Cancer Center
Studies
Open first, then newest update. How each study uses BO-112 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)Active, not recruitingPhase 2Highlight TherapeuticsNCT06422936Written as BO-112
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT04420975Written as Nanoplexed Poly I:C BO-112
- BO-112 With Pembrolizumab in Unresectable Malignant MelanomaCompletedPhase 2Highlight TherapeuticsNCT04570332Written as BO-112 plus pembrolizumab
- Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver MetastasisTerminatedPhase 2Highlight TherapeuticsNCT04508140Written as BO-112 with pembrolizumab
- Exploratory Study of BO-112 in Adult Patients With Aggressive Solid TumorsCompletedPhase 1Highlight TherapeuticsNCT02828098Written as Part 1: BO-112
- BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerTerminatedEarly Phase 1Jonsson Comprehensive Cancer CenterNCT04777708Written as Nanoplexed Poly I:C BO-112
Codes
What other systems call BO-112 · ClinicalTrials.gg INT002018
- MeSH (NLM) C000727548BO-112One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000727548 | BO-112 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.